Mechanisms in endocrinology: Epidemiology of hormonal contraceptives-related venous thromboembolism

European Journal of Endocrinology

Volumn 171, Issue 6, 2014, Pages R221-R230

  Hugon Rodin, Justine ^a   Gompel, Anne ^a   Plu Bureau, Geneviève ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Port Royal Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTRADIOL PLUS NOMEGESTROL ACETATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETONOGESTREL; ETYNODIOL DIACETATE; GESTAGEN; GESTODENE; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; MESTRANOL; MESTRANOL PLUS NORETHISTERONE; NORETHISTERONE; NORETYNODREL; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; UNINDEXED DRUG;

ARTICLE; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG FORMULATION; DRUG POTENCY; DRUG USE; ESTROGEN ACTIVITY; FIRST PASS EFFECT; HEMOSTASIS; HORMONAL CONTRACEPTION; LUNG EMBOLISM; RISK ASSESSMENT; THROMBOGENICITY; TRANSDERMAL PATCH; VAGINA RING; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLASSIFICATION; CONTRACEPTION; DRUG ADMINISTRATION ROUTE; FEMALE; FRANCE; HUMAN; PROCEDURES; RISK FACTOR; TRENDS;

CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DRUG ADMINISTRATION ROUTES; FEMALE; FRANCE; HUMANS; PROGESTINS; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84911980136     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0527     Document Type: Article

References (54)

1. Arie S. French doctors are told to restrict use of third and fourth generation oral contraceptives. BMJ 2013 346 f121. (doi:10.1136/bmj.f121)
2. Arie S. European agency defends existing advice on later generation contraceptive pills. BMJ 2013 346 f279. (doi:10.1136/bmj.f279)
3. Bitzer J & Simon JA. Current issues and available options in combined hormonal contraception. Contraception 2011 84 342-356. (doi:10.1016/j.contraception.2011.02.013)
4. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thrombosis and Haemostasis 2000 83 657-660.
5. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR & Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis 2007 5 692-699. (doi:10.1111/j.1538-7836.2007.02450.x)
6. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE & Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011 343 d6423. (doi:10.1136/bmj.d6423)
7. Whalen KL & Rose R. Estradiol valerate/dienogest: a novel oral contraceptive. Annals of Pharmacotherapy 2011 45 1256-1261. (doi:10.1345/aph.1Q216)
8. Mueck AO & Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011 76 531-539. (doi:10.1016/j.steroids.2011.02.002)
9. Chabbert-Buffet N, Chassard D, Ochsenbein E, Thomas JL & Christin-Maitre S. Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: a double-blind, randomised, dose-finding pilot study. European Journal of Contraception & Reproductive Health Care 2011 16 76-84. (doi:10.3109/13625187.2011.554923)
10. Edgren RA & Stanczyk FZ. Nomenclature of the gonane progestins. Contraception 1999 60 313. (doi:10.1016/S0010-7824(99)00101-8)
11. Sitruk-Ware R & Nath A. The use of newer progestins for contraception. Contraception 2010 82 410-417. (doi:10.1016/j.contraception.2010.04.004)
12. Grimes DA, Lopez LM, O'Brien PA & Raymond EG. Progestin-only pills for contraception. Cochrane Database of Systematic Reviews 2013 11 CD007541. (doi:10.1002/14651858.CD007541.pub3)
13. Sitruk-Ware R & Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Practice & Research. Clinical Endocrinology & Metabolism 2013 27 13-24. (doi:10.1016/j.beem.2012.09.004)
14. Sitruk-Ware R, Plu-Bureau G, Menard J, Conard J, Kumar S, Thalabard JC, Tokay B & Bouchard P. Effects of oral and transvaginal ethinyl-estradiol on hemostatic factors and hepatic proteins in a randomized cross-over study. Journal of Clinical Endocrinology and Metabolism 2007 92 2074-2079. (doi:10.1210/jc.2007-0026)
15. Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG & Siiteri PK. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception 2003 67 93-99. (doi:10.1016/S0010-7824(02)00473-0)
16. Stanczyk FZ & Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception 2014 89 242-252.
17. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T & Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013 347 f5298. (doi:10.1136/bmj.f5298)
18. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T & Dekkers OM. Combined oral contraceptives: venous thrombosis. Cochrane Database of Systematic Reviews 2014 3 CD010813. (doi:10.1016/j.contraception.2013.12.003)
19. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J & Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Practice & Research. Clinical Endocrinology & Metabolism 2013 27 25-34. (doi:10.1016/j.beem.2012.11.002)
20. Martinez F, Ramirez I, Perez-Campos E, Latorre K & Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. European Journal of Contraception & Reproductive Health Care 2012 17 7-29. (doi:10.3109/13625187.2011.643836)
21. Wu CQ, Grandi SM, Filion KB, Abenhaim HA, Joseph L & Eisenberg MJ. Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. BJOG: an International Journal of Obstetrics and Gynaecology 2013 120 801-810. (doi:10.1111/1471-0528.12210)
22. van Hylckama Vlieg A &Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? Journal of Thrombosis and Haemostasis 2011 9 257-266. (doi:10.1111/j.1538-7836.2010.04148.x)
23. Plu-Bureau G, Amiral J, Guize L & Scarabin PY. Safety of combined oral contraceptive pills. Lancet 1996 347 549. (doi:10.1016/S0140-6736(96)91182-4)
24. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, Rosing J & Grobbee DE. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 2004 103 927-933. (doi:10.1182/blood-2003-04-1285)
25. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Buller HR, PrinsMH et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999 354 2036-2040. (doi:10.1016/S0140-6736(99)06092-4)
26. Oral contraceptive and hemostasis study group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003 67 173-185. (doi:10.1016/S0010-7824(02)00476-6)
27. Odlind V, Milsom I, Persson I & Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstetricia et Gynecologica Scandinavica 2002 81 482-490.
28. Raps M, Helmerhorst F, Fleischer K, Thomassen S, Rosendaal F, Rosing J, Ballieux B & VAN Vliet H. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. Journal of Thrombosis and Haemostasis 2012 10 992-997. (doi:10.1111/j.1538- 7836.2012.04720.x)
29. van Vliet HA, Frolich M, Christella M, Thomassen LG, Doggen CJ, Rosendaal FR, Rosing J & Helmerhorst FM. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Human Reproduction 2005 20 563-568. (doi:10.1093/humrep/deh612)
30. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R & Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996 54 5-13.
31. Farmer RD, Lawrenson RA, Todd JC,Williams TJ, MacRae KD, Tyrer F & Leydon GM. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. British Journal of Clinical Pharmacology 2000 49 580-590. (doi:10.1046/j.1365-2125.2000.00198.x)
32. Lidegaard O, Edstrom B & Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002 65 187-196. (doi:10.1016/S0010-7824(01)00307-9)
33. Jick SS, Kaye JA, Russmann S & Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006 73 566-570. (doi:10.1016/j.contraception.2006.02.002)
34. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ & Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009 339 b2921. (doi:10.1136/bmj. b2921)
35. Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S & Cushman M. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstetrics and Gynecology 2008 111 278-284. (doi:10.1097/AOG.0b013e3181626d1b)
36. Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, Blankenstein MA & Fauser BC. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Human Reproduction Update 2014 20 76-105. (doi:10.1093/humupd/dmt038)
37. Janaud A, Rouffy J, Upmalis D & Dain MP. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstetricia et Gynecologica Scandinavica. Supplement 1992 156 33-38. (doi:10.3109/00016349209156513)
38. Wiegratz I, Jung-Hoffmann C & Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995 51 341-346. (doi:10.1016/0010-7824(95)00098-U)
39. Coenen CM, Thomas CM, Borm GF, Hollanders JM & Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996 53 171-176. (doi:10.1016/0010-7824(96)00006-6)
40. White T, Jain JK & Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. American Journal of Obstetrics and Gynecology 2005 192 2055-2059. (doi:10.1016/j.ajog.2005.02.067)
41. Greco T, Graham CA, Bancroft J, Tanner A & Doll HA. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 2007 76 8-17. (doi:10.1016/j.contraception.2007.04.002)
42. Granger LR, Roy S & Mishell DR Jr. Changes in unbound sex steroids and sex hormone binding globulin - binding capacity during oral and vaginal progestogen administration. American Journal of Obstetrics and Gynecology 1982 144 578-584.
43. Hammond GL, Langley MS, Robinson PA, Nummi S & Lund L. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertility and Sterility 1984 42 44-51.
44. Song S, Chen JK, Yang PJ, He ML, Li LM, Fan BC, Rekers H & Fotherby K. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception 1992 45 523-532. (doi:10.1016/0010-7824(92)90103-Z)
45. Rickenlund A, Carlstrom K, Ekblom B, Brismar TB, Von Schoultz B & Hirschberg AL. Effects of oral contraceptives on body composition and physical performance in female athletes. Journal of Clinical Endocrinology and Metabolism 2004 89 4364-4370. (doi:10.1210/jc.2003-031334)
46. Strufaldi R, Pompei LM, Steiner ML, Cunha EP, Ferreira JA, Peixoto S & Fernandes CE. Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. Contraception 2010 82 147-154. (doi:10.1016/j.contraception.2010.02.016)
47. Agren UM, Anttila M, Maenpaa-Liukko K, Rantala ML, Rautiainen H, Sommer WF & Mommers E. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. European Journal of Contraception & Reproductive Health Care 2011 16 444-457. (doi:10.3109/13625187.2011.604450)
48. Todd J, Lawrenson R, Farmer RD, Williams TJ & Leydon GM. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Human Reproduction 1999 14 1500-1505. (doi:10.1093/humrep/14.6.1500)
49. Bloemenkamp KW, Rosendaal FR, Buller HR, Helmerhorst FM, Colly LP & Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Archives of Internal Medicine 1999 159 65-70. (doi:10.1001/archinte.159.1.65)
50. Heuner A, Kuhnz W, Heger-Mahn D, Richert K & Humpel M. A singledose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. Advances in Contraception 1995 11 207-225. (doi:10.1007/BF01978421)
51. Spona J, FeichtingerW, Kindermann C, Wunsch C & Brill K. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception 1996 54 299-304. (doi:10.1016/S0010-7824(96)00183-7)
52. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M & Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception 1999 60 255-262. (doi:10.1016/S0010-7824(99)00093-1)
53. Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH & Kuhl H. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003 67 25-32. (doi:10.1016/S0010-7824(02)00436-5)
54. Elkind-Hirsch KE, Darensbourg C, Ogden B, Ogden LF & Hindelang P. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception 2007 76 348-356. (doi:10.1016/j.contraception.2007.08.001)